IDH1 and cholangiocarcinoma: In August 2021, the Food and Drug Administration (FDA) approved the mutant-IDH1 inhibitor ivosidenib (brand name Tibsovo) for adults with previously treated, locally advanced, or metastatic CCA with an IDH1 mutation.